Wanjia Group Holdings Ltd. 0401

Twist Bioscience has seen its assessed fair value move from US$105.30 to US$109.58, a modest reset that feeds into how analysts frame the stock’s price targets. The shift comes as research coverage splits between those pointing to higher peer comparables and AI driven drug discovery potential, and others who argue that recent gains and event driven enthusiasm already price in a lot of good news. In the sections that follow, you will see how these changing targets fit into the broader Twist...

Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before markets open on Oct.9.

Neogen (NASDAQ:NEOG) shareholders approved all five proposals presented at the company’s 2026 annual meeting, including the election of three directors, advisory approval of executive compensation, and amendments to the company’s equity incentive and employee stock purchase plans. Chair of the Boar

MIAMI, October 02, 2026--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings, intending to include breast and lung cancer. The companies i

TOKYO, October 02, 2026--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer (TNBC).

MILAN & HYOGO, Japan, October 02, 2026--Italfarmaco and JCR announced an exclusive license agreement to develop and commercialize JR-141 in the United States, Europe, and Latin America.

TransMedics Group (TMDX) has drawn investor attention after recent trading left the stock around $78.64, with returns down over the past month but higher over the past three months and three years. Short term momentum for TransMedics Group has faded, with the share price return down 5.76% over one day, 6.27% over the past week and 4.38% over the past month. At the same time, a 14.20% 90 day share price return and a 54.08% three year total shareholder return point to a stock where sentiment...

BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational gene therapy, rebisufligene etisparvovec, for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A. EMA validation confirms that the application is sufficiently complete for the Agency to begin its formal scientific review. Validation

LUXEMBOURG, October 02, 2026--Regulatory News: Eurofins Scientific SE (Paris:ERF) (the "Company" or "Eurofins") (EUFI.PA) announces the completion of the divestment of its Electrical & Electronic Testing business ("MET Labs") to UL Solutions Inc., which took place on 1 October 2026. The transaction was announced on 14 April 2026 for an Enterprise Value of €575 million on a cash and debt free basis.

LUXEMBOURG, October 02, 2026--Regulatory News: Eurofins Scientific (EUFI.PA) (Paris:ERF), a global scientific leader in bioanalytical testing, announces the successful closing of its acquisition of the Life Sciences Testing Services business in North America of Element Materials Technology ("Element"), which took place on 1 October 2026. The transaction was announced on 20 July 2026 for an enterprise value of USD400m.

Green Thumb Industries (CNSX:GTII) has moved back into focus after management approved a US$50 million share repurchase program, adding a capital allocation twist to a sector that is already dealing with renewed regulatory uncertainty. Price action tells the story. Green Thumb Industries has a 1-day share price return of 3.4% after the buyback news, while the 7-day and 90-day share price returns are down 12.0% and 10.5% as regulatory delays and sector-wide caution continue to weigh on...

The analyst fair value estimate for Lexicon Pharmaceuticals has shifted from US$3.77 to US$4.55 per share, reflecting a higher modeled upside in the latest work. Recent Street commentary links this move to growing focus on sotagliflozin and the fully enrolled Phase 3 SONATA HCM trial, which has a defined data readout in 1Q27. As you read on, you will see how these factors shape the evolving Lexicon Pharmaceuticals story and what to watch as the narrative develops. Stay updated as the Fair...

Jean-Philippe Rocher Appointed Head of Pharmaceutical DevelopmentMikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 2, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment of Jean-Philippe Rocher as Head of Pharmaceutical Development and

TOULOUSE, France & FULLERTON, Calif., October 02, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 – ABNX – eligible for PEA-PME) ("Abionyx" or the "Company"), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on its exclusive apoA-I technology platform, today announces (i) a partial repayment of the principal amount of the bonds subscribed by Fenja Capital II A/S ("Fenja") and (ii) consequently, the pricing of a EUR 0.52 Million res

Abogen Biosciences ("Abogen" or the "Group"), a clinical-stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Novartis to advance RNA-encoded therapeutics. The agreement includes an exclusive worldwide license to Abogen's lead asset, ABO2203, as well as options to exclusively license other potential programs leveraging Abogen's proprietary RNA platform.

Twist Bioscience has turned into one of the market’s stronger long term performers, and the latest surge leaves a simple but important question on the table. Do the company’s current cash flows and their future potential really support today’s share price around US$188? Over the past 3 years, Twist Bioscience has delivered a gain of about 9x, which puts a lot of pressure on its cash flows to justify how far the stock has already run. The new collaboration with Eli Lilly’s TuneLab ties Twist...